Tenax Therapeutics (TENX) Cash from Financing Activities (2010 - 2026)

Tenax Therapeutics has reported Cash from Financing Activities for 15 years, with the latest figure at $13.4 million in Q2 2026.

• Cash from Financing Activities for Q2 2026 came in at $13.4 million, up 4709.71% year-over-year; the trailing twelve-month figure through Jun 2026 was $58.5 million (down 49.5% YoY), and the FY2025 annual result was $38.5 million, down 61.44% from the prior year.
• Cash from Financing Activities declined to $13.4 million in Q2 2026, from $30.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $92.0 million in Q3 2024 and troughed at -$174603.0 in Q4 2023.
• A 5-year average of $11.3 million and a median of $1.7 million in 2025 frame the typical range for Cash from Financing Activities.
• The widest annual swing landed in 2023, when Cash from Financing Activities slumped 8563.55%; it then surged 53820.45% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $2063.0 in 2022, then slumped by 8563.55% to -$174603.0 in 2023, then soared by 138.37% to $67000.0 in 2024, then surged by 17229.85% to $11.6 million in 2025, then increased by 15.16% to $13.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $13.4 million in Q2 2026, $30.5 million in Q1 2026, and $11.6 million in Q4 2025.